There are 2 articles on this stock available only to PRO subscribers.
PR Newswire (Wed, 8:05AM)
Leader in Targeted Drug Development, Peter Hirth, Ph.D., Joins Trovagene's Scientific Advisory BoardPR Newswire (Aug 12, 2014)
PR Newswire (Aug 7, 2014)
PR Newswire (Jul 30, 2014)
PR Newswire (Jul 1, 2014)
PR Newswire (Jun 16, 2014)
PR Newswire (Jun 2, 2014)
PR Newswire (May 28, 2014)
Mon, Aug. 18, 12:46 PM
Mon, Aug. 18, 12:08 PM
- Shares of thinly-traded nano cap Trovagene (TROV +23.1%) jump on a 6x surge in volume albeit on turnover of only ~450K. Prices have rebounded ~50% from the August 1, 2014 low of $2.97. Shares peaked at $10.27 about a year ago (August 5, 2013).
- The firm is developing tests to detect cell-free DNA in urine samples.
- The company offers testing services via its in-house laboratory. It launched an LDT for the KRAS oncogene in March 2014, BRAF V600E in October 2013 and HPV in March 2013. It has yet to generate revenue from any of them, however. Its Q2 revenue of ~$56K consisted of royalties (NPM1) and a license fee ($10K).
Fri, Aug. 8, 8:01 AM
Tue, Jul. 1, 12:09 PM| Comment!
Tue, May. 20, 11:55 AM
- In what appears to be a hand-picked six-patient subset of a study of the prevalence of the BRAF V600E mutation in Erdheim-Chester disease, MD Anderson Cancer Center's Filip Janku finds that Trovagene's (TROV -2.4%) urine-based cell-free nucleic test for the mutation agrees with the six biopsy results. The theory is that the non-invasive diagnostic might be clinically useful considering that 60% of biopsies fail to provide enough tissue for testing.
- The fact that the company has yet generate any revenue from the BRAF testing service it launched six months ago reinforces the embryonic nature of urine-based oncogene testing. There is much work to be done to validate its clinical usefulness.
Fri, May. 16, 4:03 PM
- Shares of thinly traded nano cap Trovagene (TROV -8.8%) continue their slide today on 4x higher volume. Prices have now cratered 66% from the $10.27 August 5 high.
- The company reported Q1 results earlier in the week. Notable by their absence are any revenues from its much-ballyhooed transrenal nucleic acid tests. It launched a BRAF test in its CLIA lab in October of last year and a KRAS test in March, but no revenues have been generated yet. Per its 10-Q, all of its $111K in revenues come from NPM1 royalties.
Mon, May. 12, 6:06 PM
Mon, Mar. 17, 4:17 PM
Mon, Mar. 17, 8:27 AM
- Nano cap biotech Trovagene (TROV) debuts a KRAS genetic test that utilizes a urine sample instead of blood or tissue. The company offers the test as a service (laboratory-developed test). It detects the seven most common mutations in the KRAS oncogene.
- Consensus revenue estimates for 2013 and 2014 are $360K and $4.2M, respectively.
- 24 mutual funds have positions, up from 11 a year ago.
Nov. 15, 2013, 3:09 PM
- Trovagene (TROV +13.1%) is up double-digits after briefly trading in negative territory to start the day.
- The company reported a Q3 loss that was wider-than-expected Thursday evening, but that's not enough to make Aegis lose faith.
- "Although the firm's revenues were in-line with our modest estimates, the [wider] loss per share ... was driven primarily by higher-than-projected G&A spending [and the] negative impact of $1.3M from the change in fair value of warrants," analyst Raghuram Selvaraju says, before reiterating "revenue projections of $500K in 2013 and $4.6M in 2014."
- Buy rating maintained.
- Price target is $10.
Nov. 14, 2013, 4:15 PM
Oct. 1, 2013, 12:56 PM
- Shares of Trovagene (TROV +16.6%) soar as the company announces the availability of the first urine test for cancer mutation monitoring.
- The cell-free BRAF test detects and monitors V600E BRAF mutation, replacing tissue sample-based monitoring which "has limited practicality for patient monitoring due to costs, tumor heterogeneity and potential complications from the biopsy process." (PR)
- Aegis' Raghuram Selvaraju says the news marks "a significant milestone for the company and [is] a core component of the firm's strategy aimed at attaining profitability near-term."
Oct. 1, 2013, 12:47 PM
Sep. 6, 2013, 12:53 PM
- TrovaGene (TROV -0.1%) says it's partnering with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using itss cell-free DNA assays.
- The study is designed to demonstrate that cell-free DNA obtained from urine is a viable systemic sample for colorectal cancer disease monitoring, which includes measuring therapy response, identifying cancer genomic changes and monitoring disease progression.
Aug. 30, 2013, 2:32 PM
- Shares of TrovaGene (TROV -12.7%) have moved steadily lower throughout the session and are now down double-digits on twice their average 10-day volume.
- Perhaps weighing on sentiment is an ostensibly bullish article from SA contributor Douglas House which, upon a closer read, has some rather disconcerting things to say about the company's prospects.
- House flags "nosebleed" numbers for price/ book, revenue/ share, price/ to sales, and revenue/ employee and characterizes the status of TrNA testing as "embryonic."
- After a lengthy review, the author does note several "TROV-specific events [that should] bolster the company's prospects over the next 1-2 years," but it's probably the last paragraph that comes across the most bearish: "This stock is not for buy-and-hold types because of its speculative nature [and] if you hold onto your position expecting to see ... the company blossoming into the next Celgene, it ain't going to happen."
Aug. 30, 2013, 12:45 PM
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
TROV vs. ETF Alternatives
Other News & PR